Due to the low density of envelope (Env) spikes on the surface of HIV-1, neutralizing IgG antibodies rarely bind bivalently using both antigen-binding arms (Fabs) to crosslink between spikes (inter-spike crosslinking), instead resorting to weaker monovalent binding that is more sensitive to Env mutations. Synthetic antibodies designed to bivalently bind a single Env trimer (intra-spike crosslinking) were previously shown to exhibit increased neutralization potencies. In initial work, diFabs joined by varying lengths of rigid double-stranded DNA (dsDNA) were considered. Anticipating future experiments to improve synthetic antibodies, we investigate whether linkers with different rigidities could enhance diFab potency by modeling DNA-Fabs con...
Despite decades of effort, no current vaccine elicits neutralizing antibodies at concentrations blo...
SummaryAntibodies developed during HIV-1 infection lose efficacy as the viral spike mutates. We post...
Despite decades of effort, no current vaccine elicits neutralizing antibodies at concentrations blo...
Due to the low density of envelope (Env) spikes on the surface of HIV-1, neutralizing IgG antibodies...
IgG antibodies increase their apparent affinities by using both of their Fabs to simultaneously atta...
IgG antibodies increase their apparent affinities by using both of their Fabs to simultaneously atta...
Due to the low density of envelope (Env) spikes on the surface of HIV-1, neutralizing IgG antibodies...
Due to the low density of envelope (Env) spikes on the surface of HIV-1, neutralizing IgG antibodies...
Due to the low density of envelope (Env) spikes on the surface of HIV-1, neutralizing IgG antibodies...
Due to the low density of envelope (Env) spikes on the surface of HIV-1, neutralizing IgG antibodies...
Antibodies developed during HIV-1 infection lose efficacy as the viral spike mutates. We postulated ...
Antibodies developed during HIV-1 infection lose efficacy as the viral spike mutates. We postulated ...
Monoclonal antibodies b12 and 4E10 are broadly neutralizing against a variety of strains of the huma...
Monoclonal antibodies b12 and 4E10 are broadly neutralizing against a variety of strains of the huma...
Despite decades of effort, no current vaccine elicits neutralizing antibodies at concentrations blo...
Despite decades of effort, no current vaccine elicits neutralizing antibodies at concentrations blo...
SummaryAntibodies developed during HIV-1 infection lose efficacy as the viral spike mutates. We post...
Despite decades of effort, no current vaccine elicits neutralizing antibodies at concentrations blo...
Due to the low density of envelope (Env) spikes on the surface of HIV-1, neutralizing IgG antibodies...
IgG antibodies increase their apparent affinities by using both of their Fabs to simultaneously atta...
IgG antibodies increase their apparent affinities by using both of their Fabs to simultaneously atta...
Due to the low density of envelope (Env) spikes on the surface of HIV-1, neutralizing IgG antibodies...
Due to the low density of envelope (Env) spikes on the surface of HIV-1, neutralizing IgG antibodies...
Due to the low density of envelope (Env) spikes on the surface of HIV-1, neutralizing IgG antibodies...
Due to the low density of envelope (Env) spikes on the surface of HIV-1, neutralizing IgG antibodies...
Antibodies developed during HIV-1 infection lose efficacy as the viral spike mutates. We postulated ...
Antibodies developed during HIV-1 infection lose efficacy as the viral spike mutates. We postulated ...
Monoclonal antibodies b12 and 4E10 are broadly neutralizing against a variety of strains of the huma...
Monoclonal antibodies b12 and 4E10 are broadly neutralizing against a variety of strains of the huma...
Despite decades of effort, no current vaccine elicits neutralizing antibodies at concentrations blo...
Despite decades of effort, no current vaccine elicits neutralizing antibodies at concentrations blo...
SummaryAntibodies developed during HIV-1 infection lose efficacy as the viral spike mutates. We post...
Despite decades of effort, no current vaccine elicits neutralizing antibodies at concentrations blo...